GlaxoSmithKline News | finanzen.ch

GlaxoSmithKline Aktie VALOR 1102657 / ISIN GB0009252882

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

30.07.25	Pharmakonzern GSK überrascht im Quartal - steigende Zuversicht (AWP)
30.07.25	GSK delivers continued strong performance (EN, GlaxoSmithKline)
29.07.25	GSK highlights new findings on Dementia and Alzheimer’s Disease at AAIC 2025, building on leadership in immunology and inflammation (EN, GlaxoSmithKline)
28.07.25	GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology (EN, GlaxoSmithKline)
24.07.25	Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
23.07.25	GSK announces extension of US Food and Drug Administration review period for Blenrep (belantamab mafodotin-blmf) in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
17.07.25	GSK provides update on US FDA advisory committee review of Blenrep (belantamab mafodotin-blmf) combinations for patients with relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
17.07.25	US FDA approves GSK’s Shingrix in a prefilled syringe presentation (EN, GlaxoSmithKline)
14.07.25	US FDA accepts application to review expanded use of GSK’s RSV vaccine, Arexvy, for adults 18-49 at increased risk (EN, GlaxoSmithKline)
08.07.25	ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025 (EN, GlaxoSmithKline)
07.07.25	GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) (EN, GlaxoSmithKline)
25.06.25	Price of world’s first malaria vaccine (RTS,S) for children in endemic countries to be reduced by more than half, to less than $5 (EN, GlaxoSmithKline)
23.06.25	Linerixibat accepted for review by the European Medicines Agency for cholestatic pruritus in patients with primary biliary cholangitis (PBC) (EN, GlaxoSmithKline)
20.06.25	Japan’s Ministry of Health, Labour and Welfare accepts regulatory application to expand use of GSK’s RSV vaccine, Arexvy, in adults aged 18-49 at increased risk of severe RSV disease (EN, GlaxoSmithKline)
13.06.25	GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older (EN, GlaxoSmithKline)
12.06.25	GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development (EN, GlaxoSmithKline)
02.06.25	Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC) (EN, GlaxoSmithKline)
29.05.25	GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio (EN, GlaxoSmithKline)
28.05.25	PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee (EN, GlaxoSmithKline)
26.05.25	Wem gehört eigentlich der Corona-Impfstoffentwickler CureVac? - Das sind die bedeutendsten Anteilseigner (finanzen.ch) Dem Biomedizin-Spezialisten CureVac aus Tübingen gelang 2020 einer der beeindruckendsten Börsengänge eines deutschen Unternehmens seit langem. Wer sind eigentlich die grössten Anteilseigner des Impfstoffentwicklers?» mehr
23.05.25	Blenrep (belantamab mafodotin) combinations receive positive CHMP opinion in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
21.05.25	Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD) (EN, GlaxoSmithKline)
19.05.25	Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
14.05.25	GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) (EN, GlaxoSmithKline)
13.05.25	GSK provides update on belrestotug development programme (EN, GlaxoSmithKline)
08.05.25	GLISTEN phase III trial results show linerixibat significantly improves cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) (EN, GlaxoSmithKline)
02.05.25	GSK continues to advance the future of respiratory medicine and patient care with new data at ATS (EN, GlaxoSmithKline)
30.04.25	Nucala (mepolizumab) delivers clinically meaningful and statistically significant reduction in COPD exacerbations, with positive MATINEE trial results published in New England Journal of Medicine (EN, GlaxoSmithKline)
30.04.25	GSK verdient zum Jahresauftakt überraschend viel (AWP)
30.04.25	GSK makes strong start to 2025 with growth in sales, profits and earnings (EN, GlaxoSmithKline)
17.04.25	Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
16.04.25	GSK’s 5-in-1 meningococcal vaccine Penmenvy receives positive recommendation from US Advisory Committee on Immunization Practices (EN, GlaxoSmithKline)
25.03.25	Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older (EN, GlaxoSmithKline)
25.03.25	GSK, UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to collaborate on first-of-its-kind dementia research initiative (EN, GlaxoSmithKline)
24.03.25	GSK’s application to expand use of Nucala (mepolizumab) for the treatment of COPD accepted for review by the European Medicines Agency (EN, GlaxoSmithKline)
12.03.25	ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV (EN, GlaxoSmithKline)
11.03.25	ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1 (EN, GlaxoSmithKline)
09.03.25	ViiV Healthcare continues to deliver long-acting injectable HIV innovation with late-breaking data and real-world insights across pipeline and portfolio at CROI 2025 (EN, GlaxoSmithKline)
06.03.25	GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults (EN, GlaxoSmithKline)
03.03.25	Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP) (EN, GlaxoSmithKline)
01.03.25	Depemokimab delivers clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (EN, GlaxoSmithKline)
24.02.25	GSK plc commences share buyback programme (EN, GlaxoSmithKline)
24.02.25	GSK completes acquisition of IDRx, Inc. (EN, GlaxoSmithKline)
21.02.25	GSK announces Dr Gavin Screaton to join the Board as Non-Executive Director (EN, GlaxoSmithKline)
20.02.25	Nucala (mepolizumab) application for COPD accepted for review in China (EN, GlaxoSmithKline)
15.02.25	Penmenvy, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY (EN, GlaxoSmithKline)
05.02.25	GSK überrascht positiv mit starkem Jahresschluss und höheren Zielen (AWP)
05.02.25	GSK überrascht mit starkem Jahresschluss - Prognose erhöht (AWP)
05.02.25	GSK delivers strong 2024 performance with further improvement to long-term growth outlook (EN, GlaxoSmithKline)
31.01.25	European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents (EN, GlaxoSmithKline)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	76.14	1.68 %	K V
Zurich Insur Gr	556.60	0.43 %	K V
Swiss Re	146.25	0.38 %	K V
Holcim	64.98	0.37 %	K V
Swiss Life Hldg	845.80	0.33 %	K V
UBS Group	30.44	-1.68 %	K V
Part Grp Hldg	1’101.50	-2.09 %	K V
Sika	192.60	-2.23 %	K V
CieFinRichemont	133.40	-2.63 %	K V

mehr

01.06.22		GSK-Aktie schwach: GlaxoSmithKline will Konsumentensparte Mitte Juli an die Börse bringen - Pfizer steigt aus
28.02.22		GSK-Aktie im Minus: GlaxoSmithKline beendet RSV-Impfstudie mit Schwangeren - IPO von Consumer-Health-Geschäft
09.02.22		GSK-Aktie gibt dennoch nach: GlaxoSmithKline verdient im Schlussquartal deutlich mehr
28.07.21		GSK-Aktie unbeeindruckt: GlaxoSmithKline bestätigt Prognose - EU unterschreibt Vertrag für Corona-Medikament